Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Real-World Characterization of Ibrutinib Therapy for Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) Patients in British Columbia (BC)

Rania S. Khelifi, Steven J.T. Huang, BMLSc, Kerry J. Savage, MDMSc, Diego Villa, MDMPH, David W. Scott, MBChB, PhD, Khaled Ramadan, MBBCH, MRCP, FRCPath, Joseph M. Connors, MD, Laurie H. Sehn, MDMPH, Cynthia L Toze, MD FRCPC, Alina S. Gerrie, MD MPH

Blood (2020) 136 (Supplement 1): 33–34.

https://doi.org/10.1182/blood-2020-138887

Published: 2020

Journal Articles

Identification of LAG3+ T Cell Populations in the Tumor Microenvironment of Classical Hodgkin Lymphoma and B-Cell Non-Hodgkin Lymphoma

Katsuyoshi Takata, MD PhD, Tomohiro Aoki, MD PhD, Lauren C. Chong, MSc, Katy Milne, Tomoko Miyata-Takata, MD PhD, Karanvir Singh, Talia Goodyear, Pedro Farinha, MD PhD, Graham W. Slack, MD, Laurie H. Sehn, MDMPH, Kerry J. Savage, MDMSc, Brad H Nelson, David W. Scott, MBChB, PhD, Christian Steidl, MD

Blood (2020) 136 (Supplement 1): 19.

https://doi.org/10.1182/blood-2020-141462

Published: 2020

Journal Articles

Hodgkin Variant of Richter's Transformation (HvRT) Among Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Patients in British Columbia (BC), Canada

Kai Zhu, Andrew Jamroz, Bsc, Steven J.T. Huang, BMLSc, Diego Villa, MDMPH, Ciara L. Freeman, MSc, MBBChir, David W. Scott, MBChB, PhD, Graham W. Slack, MD, Laurie H. Sehn, MDMPH, Joseph M. Connors, MD, Cynthia L. Toze, MDFRCPC,MSc, Kerry J. Savage, MDMSc, Alina S. Gerrie, MD MPH

Blood (2020) 136 (Supplement 1): 13–15.

https://doi.org/10.1182/blood-2020-141183

Published: 2020

Journal Articles

Single Cell Profiling Reveals Unique CXCL13 Positive T Cell Subsets in the Tumor Microenvironment of Lymphocyte Rich Classic Hodgkin Lymphoma

Tomohiro Aoki, MD PhD, Lauren C. Chong, MSc, Katsuyoshi Takata, MD PhD, Katy Milne, Elizabeth Chavez, BSc, Cg RT, Tomoko Miyata-Takata, MD PhD, Susana Ben-Neriah, BSc, Doria Unrau, Adele Telenius, Merrill Boyle, BSc, Pedro Farinha, MD PhD, Andrew P. Weng, MD, Kerry J. Savage, MDMSc, David W. Scott, MBChB, PhD, Sohrab P Shah, Brad H. Nelson, Christian Steidl, MD

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-134929

Published: 2020

Journal Articles

Brentuximab Vedotin with Chemotherapy for Patients with Previously Untreated, Stage III/IV Classical Hodgkin Lymphoma: 5-Year Update of the ECHELON-1 Study

Blood (2020) 136 (Supplement 1): 26–28.

https://doi.org/10.1182/blood-2020-137089

Published: 2020

Journal Articles

Preliminary Results of a Phase 2 Study of Camidanlumab Tesirine (Cami), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Hodgkin Lymphoma

Alex F. Herrera, MD, Carmelo Carlo-Stella, MD, Graham P. Collins, MD DPhil, Kami J. Maddocks, MD, Nancy L. Bartlett, MD, Kerry J. Savage, MDMSc, Paolo F Caimi, Brian T. Hess, MD, Pier Luigi Zinzani, MD, Hans G Cruz, Luqiang Wang, Jay Feingold, Jens Wuerthner, Stephen M. Ansell, MD PhD

Blood (2020) 136 (Supplement 1): 21–23.

https://doi.org/10.1182/blood-2020-137451

Published: 2020

Journal Articles

Updates from Ongoing, First-in-Human Phase 1 Dose Escalation and Expansion Study of TTI-621, a Novel Biologic Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies

Blood (2020) 136 (Supplement 1): 41–43.

https://doi.org/10.1182/blood-2020-136198

Published: 2020

Journal Articles

Cardiac Morbidity in Adolescents and Young Adult Survivors of Hodgkin Lymphoma

Kristin C. Marr, MD, Jonathan Simkin, MPH, Andrea C. Lo, MD, Joseph M. Connors, MD, Alina S. Gerrie, MD MPH, Diego Villa, MDMPH, Ciara L. Freeman, MSc, MBBChir, David W. Scott, MBChB, PhD, Greg Hapgood, BMBS, FRACP, FRCPA, Laurie H. Sehn, MDMPH, Ryan Woods, MSc PhD, Kerry J. Savage, MDMSc

Blood (2020) 136 (Supplement 1): 18–19.

https://doi.org/10.1182/blood-2020-136454

Published: 2020

Journal Articles

Nivolumab Combined with Brentuximab Vedotin for Relapsed/Refractory Mediastinal Gray Zone Lymphoma: Primary Efficacy and Safety Analysis of the Phase 2 CheckMate 436 Study

Armando Santoro, Alison J. Moskowitz, MD, Silvia Ferrari, MD, Carmelo Carlo-Stella, MD, Michelle A. Fanale, MD, Stephen Francis, Mariana Sacchi, MD, Kerry J. Savage, MDMSc

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-137653

Published: 2020

Journal Articles

Comprehensive MYC and BCL2 Genetic Profiling in De Novo Diffuse Large B-Cell Lymphoma Demonstrates Clinically Relevant Genetic Alterations According to Cell of Origin Subtype

Daisuke Ennishi, MD PhD, Anja Mottok, MD, Kerry J. Savage, MDMSc, Susana Ben-Neriah, Hennady Shulha, Pedro Farinha, MD, Fong Chun Chan, MSc, Barbara Meissner, Merrill Boyle, BSc, Christoffer E Hother, MD PhD, Robert Kridel, MD MPH, Ryan Morin, PhD, Marco A Marra, PhD, Laurie H. Sehn, Christian Steidl, MD, Joseph M. Connors, MD, David W Scott, MBChB, PhD, Randy D. Gascoyne

Blood (2015) 126 (23): 109.

https://doi.org/10.1182/blood.V126.23.109.109

Published: 2015

Journal Articles

Genetic Alterations of Gα13 Signaling Pathway with BCL2 over-Expression Confers Lymphoma Dissemination and Inferior Outcome in Germinal Center B Cell Diffuse Large B Cell Lymphoma

Daisuke Ennishi, MD PhD, Anja Mottok, MD, Hennady Shulha, Pedro Farinha, MD, Fong Chun Chan, MSc, Barbara Meissner, Merrill Boyle, BSc, Susana Ben-Neriah, Christoffer E Hother, MD PhD, Robert Kridel, MD MPH, Ryan Morin, PhD, Marco A Marra, PhD, Kerry J. Savage, MDMSc, Laurie H. Sehn, Joseph M. Connors, MD, Christian Steidl, MD, David W Scott, MBChB, PhD, Randy D. Gascoyne

Blood (2015) 126 (23): 111.

https://doi.org/10.1182/blood.V126.23.111.111

Published: 2015

Journal Articles

Flow Cytometric Characterization of 129 Cases of Peripheral T Cell Lymphoma Not Otherwise Specified (PTCL NOS) and Angioimmunoblastic T Cell Lymphoma (AITL)

Greg Hapgood, MD, Anja Mottok, MD, Graham W Slack, MD, Randy D. Gascoyne, Christian Steidl, MD, Kerry J. Savage, MDMSc, Andrew P. Weng, MD PhD

Blood (2015) 126 (23): 2667.

https://doi.org/10.1182/blood.V126.23.2667.2667

Published: 2015

Journal Articles

ABVD Chemotherapy Results in Excellent Outcomes with Reduced Radiation Therapy Rates in Children, Adolescents and Young Adults with Hodgkin Lymphoma

Kristin C. Marr, MD, Joseph M. Connors, MD, Karen J. Goddard, MD, Kerry J. Savage, MDMSc, Rebecca J. Deyell, MD

Blood (2015) 126 (23): 2695.

https://doi.org/10.1182/blood.V126.23.2695.2695

Published: 2015

Journal Articles

Outcome of Observation As Initial Strategy in Patients with Mantle Cell Lymphoma

Pau Abrisqueta, MD, Graham W Slack, MD, David W Scott, MBChB, PhD, Randy D. Gascoyne, Joseph M. Connors, MD, Laurie H. Sehn, Kerry J. Savage, MDMSc, Diego Villa, MDMPH

Blood (2015) 126 (23): 2699.

https://doi.org/10.1182/blood.V126.23.2699.2699

Published: 2015

Journal Articles

A Phase 1 Study of the Anti-CD37 Antibody-Drug Conjugate AGS67E in Advanced Lymphoid Malignancies. Interim Results

Ahmed Sawas, MD, Kerry J. Savage, MDMSc, Raymond Perez, MD, Ranjana H Advani, MD, Anna Butturini, MD, Jacqueline Lackey, Fabio Trave, MD, Banmeet Anand, PhD, Yao Huang, Leonard Reyno, MD, Owen A. O'Connor, MD

Blood (2015) 126 (23): 3976.

https://doi.org/10.1182/blood.V126.23.3976.3976

Published: 2015

Journal Articles

Maintenance Rituximab Following R-CHOP Chemotherapy in Patients with Composite or Discordant, Indolent and Aggressive, B-Cell Non-Hodgkin Lymphomas

Roopesh R. Kansara, MD, Joseph M. Connors, MD, Kerry J. Savage, MDMSc, David W Scott, MBChB, PhD, Randy D. Gascoyne, Alina S Gerrie, MD, Laurie H. Sehn, Diego Villa, MDMPH

Blood (2015) 126 (23): 3950.

https://doi.org/10.1182/blood.V126.23.3950.3950

Published: 2015

Journal Articles

Five-Year Survival Data Demonstrating Durable Responses from a Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Hodgkin Lymphoma

Robert Chen, Ajay K. Gopal, MD, Scott E. Smith, Stephen Ansell, MD PhD, Joseph D. Rosenblatt, Kerry J. Savage, MDMSc, Joseph M. Connors, MD, Andreas Engert, Emily K Larsen, Dirk Huebner, Abraham Fong, Anas Younes, MD

Blood (2015) 126 (23): 2736.

https://doi.org/10.1182/blood.V126.23.2736.2736

Published: 2015

Journal Articles

Retrospective Analysis of Lymphomas in the Setting of Autoimmune Disease and the Impact of Immunosuppression

Adam M. Petrich, MD, Stefan Klaus Barta, MDMRCP,MS, Frederick Lansigan, MD, Trent Wang, MD, Ananta Bhatt, MD, Garrett Wasp, MD, Addie Hill, MD, Frank C. Passero, Jr., MD, Amrit Kahalon, MD, Roopesh R. Kansara, MD, Mitul Gandhi, MD, Graham W. Slack, MD, Tatyana Feldman, MD, Andrew M. Evens, DO, MSc, Kerry J. Savage, MDMSc

Blood (2015) 126 (23): 2737.

https://doi.org/10.1182/blood.V126.23.2737.2737

Published: 2015

Journal Articles

Advanced Stage Classical Hodgkin Lymphoma Patients with a Negative PET-Scan Following Treatment with ABVD Have Excellent Outcomes without the Need for Consolidative Radiotherapy Regardless of Disease Bulk at Presentation

Kerry J. Savage, MDMSc, Joseph M. Connors, MD, Diego R Villa, MDMPH, Greg Hapgood, MD, Alina S Gerrie, MD, Tamara N Shenkier, MD, David W Scott, MBChB, PhD, Randy D. Gascoyne, Francois Benard, MD, James Morris, MD, Tom Pickles, MD, Christina Parsons, MD, Don Wilson, MD, Laurie H. Sehn

Blood (2015) 126 (23): 579.

https://doi.org/10.1182/blood.V126.23.579.579

Published: 2015

Journal Articles

The Impact of Concurrent MYC BCL2 Protein Expression on the Risk of Secondary Central Nervous System Relapse in Diffuse Large B-Cell Lymphoma (DLBCL)

Kerry J. Savage, MDMSc, Laurie H. Sehn, MDMPH, Diego Villa, MDMPH, Roopesh R. Kansara, MD, Anja Mottok, MD, Daisuke Ennishi, MDPhD, Susana Ben-Neriah, MSc, Robert Kridel, MDMPH,, Christian Steidl, MD, King L. Tan, MBBS, Nathalie Johnson, MDPhD, Graham W. Slack, MD, Joseph M. Connors, MD, Pedro Farinha, MD, David W. Scott, MBChB, PhD, Randy D. Gascoyne, MD

Blood (2014) 124 (21): 495.

https://doi.org/10.1182/blood.V124.21.495.495

Published: 2014

NARROW

Real-World Characterization of Ibrutinib Therapy for Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) Patients in British Columbia (BC)

Identification of LAG3+ T Cell Populations in the Tumor Microenvironment of Classical Hodgkin Lymphoma and B-Cell Non-Hodgkin Lymphoma

Hodgkin Variant of Richter's Transformation (HvRT) Among Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Patients in British Columbia (BC), Canada

Single Cell Profiling Reveals Unique CXCL13 Positive T Cell Subsets in the Tumor Microenvironment of Lymphocyte Rich Classic Hodgkin Lymphoma

Brentuximab Vedotin with Chemotherapy for Patients with Previously Untreated, Stage III/IV Classical Hodgkin Lymphoma: 5-Year Update of the ECHELON-1 Study

Preliminary Results of a Phase 2 Study of Camidanlumab Tesirine (Cami), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Hodgkin Lymphoma

Updates from Ongoing, First-in-Human Phase 1 Dose Escalation and Expansion Study of TTI-621, a Novel Biologic Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies

Cardiac Morbidity in Adolescents and Young Adult Survivors of Hodgkin Lymphoma

Nivolumab Combined with Brentuximab Vedotin for Relapsed/Refractory Mediastinal Gray Zone Lymphoma: Primary Efficacy and Safety Analysis of the Phase 2 CheckMate 436 Study

Comprehensive MYC and BCL2 Genetic Profiling in De Novo Diffuse Large B-Cell Lymphoma Demonstrates Clinically Relevant Genetic Alterations According to Cell of Origin Subtype

Genetic Alterations of Gα13 Signaling Pathway with BCL2 over-Expression Confers Lymphoma Dissemination and Inferior Outcome in Germinal Center B Cell Diffuse Large B Cell Lymphoma

Flow Cytometric Characterization of 129 Cases of Peripheral T Cell Lymphoma Not Otherwise Specified (PTCL NOS) and Angioimmunoblastic T Cell Lymphoma (AITL)

ABVD Chemotherapy Results in Excellent Outcomes with Reduced Radiation Therapy Rates in Children, Adolescents and Young Adults with Hodgkin Lymphoma

Outcome of Observation As Initial Strategy in Patients with Mantle Cell Lymphoma

A Phase 1 Study of the Anti-CD37 Antibody-Drug Conjugate AGS67E in Advanced Lymphoid Malignancies. Interim Results

Maintenance Rituximab Following R-CHOP Chemotherapy in Patients with Composite or Discordant, Indolent and Aggressive, B-Cell Non-Hodgkin Lymphomas

Five-Year Survival Data Demonstrating Durable Responses from a Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Hodgkin Lymphoma

Retrospective Analysis of Lymphomas in the Setting of Autoimmune Disease and the Impact of Immunosuppression

Advanced Stage Classical Hodgkin Lymphoma Patients with a Negative PET-Scan Following Treatment with ABVD Have Excellent Outcomes without the Need for Consolidative Radiotherapy Regardless of Disease Bulk at Presentation

The Impact of Concurrent MYC BCL2 Protein Expression on the Risk of Secondary Central Nervous System Relapse in Diffuse Large B-Cell Lymphoma (DLBCL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only